News Article | August 3, 2017
KCAS Bioanalytical and Biomarker Services, a leading functional service contract research organization (CRO) is pleased to announce the expansion of their Large Molecule and Biomarker services team. Mr. Frank Spriggs joins KCAS as Director of Large Molecule and Biomarker Services. Mr. Spriggs has more than 15 years involvement in Ligand Binding Assay (LBA) bioanalysis with a focus on pharmacokinetics, biomarkers, immunogenicity and quality assurance. His breath of knowledge in development and optimization of LBA methods will further strengthen KCAS’ development capability. “I am delighted Frank Spriggs has joined the growing KCAS team. Frank’s ligand binding assay expertise and product development experience positions KCAS to accelerate its growth and expansion of capabilities to serve our client’s development needs.” stated John Bucksath, CEO. Mr. Spriggs joins KCAS from AIT Bioscience where he oversaw the LBA department and their molecular biology analytical techniques and services offered. Previously he worked for Pfizer and Amgen building upon his skills in method development, validation, and analysis of protein therapeutics in pre-clinical and clinical phases of drug development. He currently holds leadership roles within the Regualtory Sciences section of American Association of Pharmaceutical Scientist (AAPS). Spriggs earned his BS in Microbiology from Ohio University and an MS in Quality Assurance and Regulatory Affairs from Temple University. “I am excited to be joining KCAS. The investment being made in the large molecule services has positioned KCAS to become the bioanalytical partner of choice in the ever expanding discipline of large molecule drug development.” stated Frank Spriggs. About KCAS KCAS Bioanalytical & Biomarker Services is a contract laboratory with 38+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com
Khan M.U.,KCAS Inc |
Bowsher R.R.,B2S Consulting |
Cameron M.,LUMIGEN |
Devanarayan V.,Abbvie Inc. |
And 9 more authors.
Bioanalysis | Year: 2015
Increasingly, commercial immunoassay kits are used to support drug discovery and development. Longitudinally consistent kit performance is crucial, but the degree to which kits and reagents are characterized by manufacturers is not standardized, nor are the approaches by users to adapt them and evaluate their performance through validation prior to use. These factors can negatively impact data quality. This paper offers a systematic approach to assessment, method adaptation and validation of commercial immunoassay kits for quantification of biomarkers in drug development, expanding upon previous publications and guidance. These recommendations aim to standardize and harmonize user practices, contributing to reliable biomarker data from commercial immunoassays, thus, enabling properly informed decisions during drug development. © 2015 Future Science Ltd.
PubMed | Womens Health Research, Minnesota Gynecology & Surgery, The Saints, Mercy Hospital and 10 more.
Type: Journal Article | Journal: Journal of minimally invasive gynecology | Year: 2016
To assess the safety and effectiveness of the Minerva Endometrial Ablation System for the treatment of heavy menstrual bleeding in premenopausal women.Multicenter, randomized, controlled, international study (Canadian Task Force classification I).Thirteen academic and private medical centers.Premenopausal women (n=153) suffering from heavy menstrual bleeding (PALM-COEIN: E, O).Patients were treated using the Minerva Endometrial Ablation System or rollerball ablation.At 1-year post-treatment, study success (alkaline hematin 80mL) was observed in 93.1% of Minerva subjects and 80.4% of rollerball subjects with amenorrhea reported by 71.6% and 49% of subjects, respectively. The mean procedure times were 3.1minutes for Minerva and 17.2minutes for rollerball. There were no intraoperative adverse events and/or complications reported.The results of this multicenter randomized controlled trial demonstrate that at the 12-month follow-up, the Minerva procedure produces statistically significantly higher rates of success, amenorrhea, and patient satisfaction as well as a shorter procedure time when compared with the historic criterion standard of rollerball ablation. Safety results were excellent and similar for both procedures.
PubMed | Ampersand Biosciences LLC, LGC Ltd, Quintiles, Pfizer and 7 more.
Type: Journal Article | Journal: The AAPS journal | Year: 2016
Multiplex ligand binding assays (LBAs) are increasingly being used to support many stages of drug development. The complexity of multiplex assays creates many unique challenges in comparison to single-plexed assays leading to various adjustments for validation and potentially during sample analysis to accommodate all of the analytes being measured. This often requires a compromise in decision making with respect to choosing final assay conditions and acceptance criteria of some key assay parameters, depending on the intended use of the assay. The critical parameters that are impacted due to the added challenges associated with multiplexing include the minimum required dilution (MRD), quality control samples that span the range of all analytes being measured, quantitative ranges which can be compromised for certain targets, achieving parallelism for all analytes of interest, cross-talk across assays, freeze-thaw stability across analytes, among many others. Thus, these challenges also increase the complexity of validating the performance of the assay for its intended use. This paper describes the challenges encountered with multiplex LBAs, discusses the underlying causes, and provides solutions to help overcome these challenges. Finally, we provide recommendations on how to perform a fit-for-purpose-based validation, emphasizing issues that are unique to multiplex kit assays.
PubMed | Eurofins, Pharma Medica, Algorithme Pharma Inc., KCAS Inc and 36 more.
Type: Congresses | Journal: Bioanalysis | Year: 2016
The 9th GCCClosed Forum was held just prior to the 2015 Workshop on Recent Issues in Bioanalysis (WRIB) in Miami, FL, USA on 13 April 2015. In attendance were 58 senior-level participants, from eight countries, representing 38 CRO companies offering bioanalytical services. The objective of this meeting was for CRO bioanalytical representatives to meet and discuss scientific and regulatory issues specific to bioanalysis. The issues selected at this years closed forum include CAPA, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, and ELNs. A summary of the industrys best practices and the conclusions from the discussion of these topics is included in this meeting report.
King L.E.,Pfizer |
Farley E.,Quintiles |
Imazato M.,Novartis |
Keefe J.,Biogen Idec |
And 4 more authors.
AAPS Journal | Year: 2014
The L4 Global Harmonization Team on reagents and their stability focused on the management of critical reagents for pharmacokinetic, immunogenicity, and biomarker ligand binding assays. Regulatory guidance recognizes that reagents are important for ligand binding assays but do not address numerous aspects of critical reagent life cycle management. Reagents can be obtained from external vendors or developed internally, but regardless of their source, there are numerous considerations for their reliable long-term use. The authors have identified current best practices and provided recommendations for critical reagent lot changes, stability management, and documentation. © 2014 American Association of Pharmaceutical Scientists.
KCAS Inc | Entity website
Your success is our mission. KCAS is committed to providing best-in-class bioanalytical services through uncompromised attention to quality ...
KCAS Inc | Entity website
KCAS has a diverse staff of 55 employees with an average tenure of 14 years. Many of our researchers, including 10 PhDs, are recognized as leading experts in their field ...
KCAS Inc | Entity website
KCAS offers custom and kit-based services for quantifying cytokines, chemokines and other biomarker in animal or human matrices. Our team of scientists use ELISA, RIA or electrochemiluminescence (ECL)-based assays to perform the bulk of our biomarker work, although other platforms, such as LC-MS/MS are available ...